- This event has passed.
Ellison Institute Insights Forum
June 16 @ 10:00 am - 11:30 amFree
• Regina Barzilay, PhD | MIT Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic)
• Clifford Hudis, MD, FACP, FASCO | American Society of Clinical Oncology
• Olga Troyanskaya, PhD | Princeton University & Flatiron Institute of the Simons Foundation
• David Agus, MD | Ellison Institute
• Anna Barker, PhD, FAACR | Ellison Institute
Dating from the 1950’s, artificial intelligence (AI) is certainly not a new concept. In fact, AI evolved to the present day over several decades with periods of both progress and paralysis. Over these decades, AI machines began to store and iterate human intelligence through neural networks and achieved deep learning to replace myriad human capabilities. OpenAI was founded in 2015 and released Chat Generative Pre-Trained Transformer (ChatGPT) in 2022. AI now clearly has everyone’s attention, including some well-founded fears for its future evolution.
During the decades when the sophistication of the algorithms and neural network-based AI of today were evolving, a similar, and synergistic movement, was occurring in oncology. Advanced technologies were fueling an unprecedented “big data tsunami” with associated advances in analytics. The big data revolution in cancer has informed, and been informed by, artificial intelligence that is now driving new, non-traditional approaches to diagnosing, treating, and preventing cancer. Although AI may well prove to be transformative for Cancer, should we worry about the concept that AI could someday advance to a point where machine intelligence surpasses human intelligence (AI evolves to become self-aware) – or is this threat the stuff of science fiction?
Join us for this Insights Forum as we explore the state of numerous efforts to apply AI to cancer, what to expect in terms of potential advances (or not) during the next decade and beyond, and what we should fear, if anything?